Loading patent…
AssigneesCambridge Enterprise Limited, Yale University
InventorsJohn Bradley, Jordan Pober, Paul Clark, Wang Min, Martin Kluger
Estimating the term…
This invention relates to the identification and characterisation of specific cellular responses which are associated with tumour necrosis factor receptor 1 (TNFR1) and tumour necrosis factor receptor 1 (TNFR2). Selective modulation of these tumour necrosis factor receptors (TNFRs) Selective modulations of these responses may be useful in the promotion or inhibition of cell growth, for example, in the treatment of disease conditions, including cardiovascular and kidney diseases. Therapeutic methods employed selective TNFR1 and TNFR2 modulators are provided, along with screening methods for the identification of selective TNFR1 and TNFR2 modulators useful in such methods.
A method of identifying and/or obtaining a compound useful in therapy comprising;
A method according to any one of the preceding claims comprising determining binding of the compound with said TNFR1 and TNFR2 polypeptides.
A method according to any one of the preceding claims comprising identifying the compound as useful in treating a disease associated with inflammation or ischaemia.
A method according to any one of the preceding claims wherein the compound is identified as useful in treating vascular or kidney disease.
A method according to any one of the preceding claims wherein the polypeptides are isolated polypeptides.
A method of identifying and/or obtaining a compound useful in the treatment of a disease condition,
A method according to any one of claims 20 to 23 wherein interaction is determined by determining binding of the TNF polypeptide with said TNFR1 and TNFR2 polypeptides in the presence of the test compound.
A method of identifying and/or obtaining a compound useful in therapy comprising;
A method of assessing a disease condition in an individual comprising;
A method of treating a disease condition in an individual comprising:
A method of treating a disease condition in an individual comprising:
Use of a selective TNFR1 agonist or a selective TNFR2 agonist in the manufacture of a medicament for use in the treatment of a disease condition.
Use of a selective TNFR1 antagonist or a selective TNFR2 antagonist in the manufacture of a medicament for use in the treatment of disease condition.
Dependencies are inferred from the claim text.